We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Humacyte, Inc. (HUMA) Stock Slides as Market Rises: Facts to Know Before You Trade
Read MoreHide Full Article
Humacyte, Inc. (HUMA - Free Report) closed at $0.48 in the latest trading session, marking a -4.26% move from the prior day. The stock fell short of the S&P 500, which registered a gain of 0.58% for the day. Elsewhere, the Dow saw an upswing of 0.49%, while the tech-heavy Nasdaq appreciated by 0.45%.
Shares of the company witnessed a loss of 17.34% over the previous month, trailing the performance of the Medical sector with its loss of 4.26%, and the S&P 500's gain of 0.84%.
Market participants will be closely following the financial results of Humacyte, Inc. in its upcoming release. The company is expected to report EPS of -$0.09, up 35.71% from the prior-year quarter. Meanwhile, our latest consensus estimate is calling for revenue of $0.86 million, up 14.67% from the prior-year quarter.
In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of -$0.4 per share and a revenue of $4.05 million, indicating changes of -53.85% and +98.48%, respectively, from the former year.
Investors should also pay attention to any latest changes in analyst estimates for Humacyte, Inc. These revisions help to show the ever-changing nature of near-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.
Based on our research, we believe these estimate revisions are directly related to near-term stock moves. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has remained steady. At present, Humacyte, Inc. boasts a Zacks Rank of #4 (Sell).
The Medical - Biomedical and Genetics industry is part of the Medical sector. With its current Zacks Industry Rank of 179, this industry ranks in the bottom 28% of all industries, numbering over 250.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.
View the Zacks #1 Rank List
Image: Bigstock
Humacyte, Inc. (HUMA) Stock Slides as Market Rises: Facts to Know Before You Trade
Humacyte, Inc. (HUMA - Free Report) closed at $0.48 in the latest trading session, marking a -4.26% move from the prior day. The stock fell short of the S&P 500, which registered a gain of 0.58% for the day. Elsewhere, the Dow saw an upswing of 0.49%, while the tech-heavy Nasdaq appreciated by 0.45%.
Shares of the company witnessed a loss of 17.34% over the previous month, trailing the performance of the Medical sector with its loss of 4.26%, and the S&P 500's gain of 0.84%.
Market participants will be closely following the financial results of Humacyte, Inc. in its upcoming release. The company is expected to report EPS of -$0.09, up 35.71% from the prior-year quarter. Meanwhile, our latest consensus estimate is calling for revenue of $0.86 million, up 14.67% from the prior-year quarter.
In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of -$0.4 per share and a revenue of $4.05 million, indicating changes of -53.85% and +98.48%, respectively, from the former year.
Investors should also pay attention to any latest changes in analyst estimates for Humacyte, Inc. These revisions help to show the ever-changing nature of near-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.
Based on our research, we believe these estimate revisions are directly related to near-term stock moves. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has remained steady. At present, Humacyte, Inc. boasts a Zacks Rank of #4 (Sell).
The Medical - Biomedical and Genetics industry is part of the Medical sector. With its current Zacks Industry Rank of 179, this industry ranks in the bottom 28% of all industries, numbering over 250.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.